Purpose of Review Arsenic, a known carcinogen and developmental toxicant, is a major threat to global health. While the contribution of arsenic exposure to chronic diseases and adverse pregnancy and birth outcomes is recognized, its ability to impair critical functions of humoral and cell-mediated immunity-including the specific mechanisms in humans-is not well understood. Arsenic has been shown to increase risk of infectious diseases that have significant health implications during pregnancy and early life. Here, we review the latest research on the mechanisms of arsenic-related immune response alterations that could underlie arsenic-associated increased risk of infection during the vulnerable periods of pregnancy and early life. Recent Findings The latest evidence points to alteration of antibody production and transplacental transfer as well as failure of T helper cells to produce IL-2 and proliferate. Summary Critical areas for future research include the effects of arsenic exposure during pregnancy and early life on immune responses to natural infection and the immunogenicity and efficacy of vaccines.
Introduction
Arsenic is a widely distributed, naturally occurring metalloid in the Earth's crust [1] . Arsenic is also readily mobilized from bedrock and soil into groundwater, making it a ubiquitous drinking water contaminant [1] . Currently, the World Health Organization's (WHO) drinking water standard for arsenic is 10 μg/L, a concentration that is exceeded in the drinking water of an estimated 200 million people worldwide [2] . Arsenic is a known human carcinogen, causing cancer at many body sites [3] [4] [5] . Arsenic also causes adverse effects in many organ systems, including the immune system. In addition to arsenic's carcinogenic and immunotoxic potential, it is also a known developmental toxicant [] that readily crosses the placenta [6] . This is important because two of the most susceptible life stages that can be critically affected by arsenic exposure are pregnancy and fetal development [7] . Pregnancy induces considerable maternal strain and causes many changes in the body, particularly with respect to the maternal immune system and metabolism [8, 9] . The developing fetus is particularly vulnerable to toxic insult because of its rapid rate of in utero development. A growing body of evidence suggests that arsenic's immunotoxic potential can occur through impairment of both cell-mediated [10] [11] [12] [13] [14] [15] [16] [17] 18 •] and humoral [19] [20] [21] [22] [23] [24] immunity. There is mounting evidence of an increased risk of infections that have significant health consequences during pregnancy and early life [25] [26] [27] , including respiratory infections [28, 29••] , gastrointestinal infections [26, 28, 30, 31 ••], and tuberculosis [32] . Despite the knowledge advancements from human studies of arsenic exposure and self-reported infections, specific mechanisms of arsenic's adverse immunological This article is part of the Topical Collection on Mechanisms of Toxicity * Christopher D. Heaney cheaney1@jhu.edu effects during pregnancy and fetal and newborn development remain poorly understood. In this systematic review, we will discuss what is known about the effects of arsenic exposure on both humoral immunity and cell-mediated immunity in mother and fetus. We will then discuss potential approaches for future research to close these knowledge gaps.
Methodology
In this systematic review, we employed the following search strategy. Our research question encompassed three main concepts: (1) immunotoxicity, (2) arsenic, and (3) in utero exposure. We limited our searches to Pubmed and English language publications. All concepts were linked with "AND" statements. For each concept, we identified a number of Medical Subject Heading (MeSH) and keyword terms and searched on all terms at once, linking the terms with "OR" statements. We limited the search to papers published after January 1, 1990 . Completion of this search strategy on November 16, 2016 returned 106 papers. Additionally, we excluded all papers related to therapeutic use of arsenic trioxide for treatment of acute myeloid leukemia. As part of the final review of papers that resulted from our search strategy, we also identified and included papers that were missed based on substantive expertise and knowledge of the arsenic and immune response literature.
Arsenic Exposure and Immune Responses Human Studies of Arsenic Exposure and Humoral Immune Response
Studies demonstrate that arsenic can affect humoral immunity in many important ways (Fig. 1) . Humoral immunity is defined as immunity imparted by antibodies and other circulating macromolecules such as complement [33] . Several studies considered the effects of arsenic exposure on antibody production and transplacental transport, specifically in the context of pregnant women and their children ( Table 1) . In one such study in Bangladesh, maternal arsenic exposure was directly associated with increased total immunoglobulin G (IgG) levels in maternal serum, but not total IgG levels in cord blood [21] . This raises the possibility that arsenic could impair maternal transplacental transport of IgG to the neonate. One possible explanation for this involves increased competition for a limited number of neonatal Fc receptors (FcRn) on Cholera-specific, diphtheria-specific, tetanus-specific, and measles-specific antibodies were also measured, and the cholera antibody vibriocidal activity was assessed. Diphtheria and tetanus-specific IgG were higher in the high arsenic-exposed group when compared to the low arsenic-exposed children as well as serum concentrations of C3 and C4. No differences were noted in the vibriocidal activity of the postimmunization antibodies of high-arsenic vs. low-arsenic-exposed children nor a difference between measles-specific igG levels. syncytiotrophoblast cells in the placenta [34, 35] . These are the receptors responsible for transplacental transport of maternal serum IgG antibodies to the developing fetus. Several past studies have observed that an increase in maternal total IgG can lead to lower transplacental transfer ratios for IgG antibodies specific to anti-tetanus [36] , anti-measles [37, 38] , and anti-lipopolysaccharide from E. coli [39] . Consistency of arsenic's effect on total immunoglobulin (Ig) levels has also been observed among non-pregnant adults, who demonstrate measurably elevated serum total IgG as well as total IgA and IgE [20] . Serum complement component 4 (C4) was also found to be elevated in arsenic patients in a 2012 paper by Islam et al.; however, complement-mediated bactericidal ability of these serum samples was lower than that of controls, indicating impairment of the various complement pathways [40] . In addition to questions about transplacental transfer of pathogen-specific IgG from mother to fetus, there remain questions about arsenic's role in impairment of maternal pathogen-specific IgG response. A 2015 study of maternal arsenic exposure and susceptibility to hepatitis E virus (HEV) IgG seroconversion during pregnancy and postpartum in Bangladesh found that the odds ratio (OR) of maternal HEV seroconversion was 2.17 (95% confidence interval 1.07, 4.39) per IQR increase in urinary inorganic arsenic plus methylated species (μg/L) [31••] . A few studies have also assessed the effect of high arsenic exposure on antibody response to vaccination among pregnant women and young children. In a 2013 study by Saha et al., antibody response to inactivated vaccines (oral cholera, intradermal tetanus, diphtheria) in Bangladeshi children was unaltered by high versus low arsenic exposure [24] . However, a reduced antibody response to live attenuated measles vaccination was observed (although not statistically significant) among children with high versus low arsenic exposure. These results suggest that arsenic may affect antibody response differently, depending on the pathogen-specific vaccine target [24] . In a US study utilizing data from NHANES, increased urinary arsenic concentration (μg/L) was related to an increased odds of IgG seronegativity (loss of antibody) for varicella zoster virus, supporting the idea that antibody protection may be lost over time, allowing VZV to reactivate with an increasing arsenic dose. However, arsenic speciation in this study is limited by high levels of undetectable concentrations for arsenite and arsenate and for mononmethylarsonate (MMA) [41] . A separate study involving NHANES data of hepatitis A virus (HAV) total antibody (IgM and IgG) seroprevalence showed that increasing urinary total arsenic concentration (μg/L) was associated with an increased odds of total HAV antibody seroprevalence [42] . The association showed consistency across strata of individuals' recall of their HAV vaccination history, suggesting that arsenic exposure may be associated with a lower protective immunity provided by the HAV immunization, which may subsequently result in HAV infection yielding a stronger total antibody response [42] . Despite the advancements made by these pioneering studies, there are still many knowledge gaps to fill in this field. For example, it is unknown what the serum Ig profile of a highly arsenic-exposed newborn is compared to newborns of mothers with low exposure to arsenic. It is also unknown what role various pathogenic exposure factors play in determining the maternal and newborn antibody response to natural infection and/or vaccination in areas of high arsenic exposure and what other co-exposures and covariates, such as micronutrient availability (including those critical for one-carbon metabolism-B vitamins, folate, etc.), may play in mediating this response. There is a need for more epidemiologic research in order to elucidate the mechanisms and pathways through which arsenic exposure can alter humoral immune response in pregnant women and their newborns.
Farzan

Animal Studies of Arsenic Exposure and Humoral Immune Response
Our literature search returned no toxicological studies of humoral immune response alterations due to arsenic exposure in animal models of pregnant females and neonates (Table 2 ). In non-pregnant adult rats and goats, however, arsenic exposure has been shown to impair humoral immunity, specifically IgG production. In male rats, arsenic can suppress secondary antibody-mediated response to T cell-dependent antigen stimulation [22] . In a 2013 study by Patra et al., the authors found that female goats exposed daily to 2 mg/kg bodyweight of arsenic for 84 days had reduced antibody levels and reduced total circulating erythrocytes and leukocytes [23] . Additionally, bone marrow cells from these goats were also found to have higher caspase-3 activity and have more nicks in their DNA, both signs of apoptosis. More animal studies, particularly in models of pregnancy, are needed to continue elucidating the drivers and pathways of altered humoral immune responses to vaccination and susceptibility to viral and bacterial challenge.
Human Studies of Arsenic Exposure and Cell-Mediated Immune Response
In Vitro Studies
Studies probing the effects of arsenic exposure on cellmediated immunity in pregnant women, developing fetuses and young children, are also scarce (Table 1) . Cell-mediated immunity is defined as an immune response wherein antigenspecific T cells and B cells along with cells of the innate immune system play a primary role in immune protection [33] . Another characteristic of this form of immunity is that is cannot be transferred passively via serum. [33] . There are laboratory-based experimental in vitro studies that have begun to assess effects of arsenic exposure on cell-mediated immunity (Table 1) ; however, their results require some level of extrapolation to arsenic-exposed human populations. Laboratory studies have shown, for example, that arsenic immunotoxicity affects critical aspects of functional cellular immunity. For example, high arsenic exposure has been shown to reduce interleukin-2 (IL-2) production-an important cytokine in cell-mediated immune function-which is associated with a decrease in T cell proliferation [43] [44] [45] and activation (Fig. 1) [46] . Briefly, such studies involve isolating peripheral blood mononuclear cells (PBMCs) from healthy human donors, culturing them in the presence of varying levels of arsenic, stimulating them with particular antigens or mitogens, then analyzing their IL-2 secretion via ELISA. Studies utilizing similar in vitro approaches have found that high arsenic concentrations are capable of altering T cell structure, including the cytoskeleton [47] . Changes in cytoskeletal arrangement could affect secretion of proteins, which may help to explain the decrease in production of certain proteins by these cells, such as IL-2 [47] . In cultures of primary human lymphocytes from healthy volunteers, arsenic was found to be more toxic to helper T (Th) cell subsets (CD4 + ) compared to cytotoxic T lymphocytes (CTL or CD8 + ), an effect that was more pronounced in women than men. This result suggests that women may be more susceptible to arsenic immunotoxicity than men [48] , although the current evidence is too limited to reach firm conclusions. Generation of T celldependent antibody responses requires orchestration of antigen processing and presentation, CD4 + T cell responses, and B cell responses [49] . Although arsenic can induce apoptosis in B cell leukemic cell lines in vitro, little is known about its alteration of B lymphocyte and plasma cell function in humans [50] .
A recent paper by Burchiel et al. [51] adds yet another level of complexity to this. In their study, they found that PBMCs from healthy donors cultured in vitro displayed differential levels of susceptibility to low-dose arsenite, as assessed by a T cell proliferation assay [51] . Using intracellular staining of activated, arsenite-treated PBMCs, the authors showed that populations of T H 1 (Tbet + ) cells and double-positive T H 17 (RoRγt + ) and T Reg (Foxp3 + ) were diminished among arsenite-susceptible individuals compared with activated, arsenite-treated PBMCs from non-susceptible individuals. This finding confirms the importance of taking interindividual variability into account in studies of arsenic immunotoxicity.
Epidemiologic Studies
While there are an abundance of in vitro studies utilizing human primary PBMCs and human cell lines, there are fewer studies that assessed cell-mediated immune effects of arsenic in exposed human populations (Table 1) . A study by Ahmed Genes and proteins associated with cell motility, cytoskeleton, and adhesion were also altered in the fetal rat lung.
Patra et al. 2013 Black Bengal Goat(s)
Female Humoral immunity 0, 2 mg/kg BW Serum IgG, hemoglobin, total erythrocyte count, and total leukocyte counts were all significantly reduced in arsenic-exposed animals. Bone marrow cells of arsenic-exposed goats were found to have higher caspase-3 activity and increased DNA nicking.
Nain et al. as an in vitro lymphoproliferation assay. This study also found a reduction in the recruitment of macrophages to the peritoneal cavity, while no effect was seen in the baseline number of macrophages present in the BALF of arsenic-exposed mice when compared with controls.
Goytia-Acevedo et al.
C57B/6 mice
Female Cell-mediated immunity 1, 10, 100, 1000nM T lymphocytes were isolated from young adult female mice and co-cultured with mitogens PHA or Con A. Authors found that at the highest doses of sodium arsenite, T lymphocytes underwent less mitogen-stimulated proliferation when pretreated (PHA and Con A) or simultaneously cultured (PHA only) with sodium arsenite.
et al. [18•] of preschool-aged children in rural Bangladesh showed that arsenic alters cell-mediated immune response to Bacillus Calmette-Guerin (BCG) vaccination as indicated by induration at the site of purified protein derivate (PPD) challenge. Briefly, the BCG vaccine was provided early in life to protect against severe tuberculosis morbidity and mortality, while PPD challenges were administered later in life as assessments of residual T cell immunologic memory in the child. In this study, increasing arsenic exposure was associated with increased odds of non-response to PPD challenge. The significance of this non-response is a failure of the BCG-specific CD4 + T cells to respond to challenge with an antigen that they have "seen" before and indicates that the BCG vaccine may no longer have been as effective in children as their arsenic exposure increased. The authors observed effect modification by child underweight status and reports of a recent infection and noted a negative but potentially non-monotonic exposureresponse association between urinary arsenic levels and serum IL-2 [ [18•] . This arsenic-IL-2 relation at low to moderate arsenic exposure levels is consistent with a study of HEV IgG seroconversion during pregnancy and pospartum conducted in a region of Bangladesh with low to moderate arsenic exposure. Among pregnant women who seroconverted to HEV, there was an increase in IL-2 levels as arsenic exposure increased [31••] . Yet, these low to moderate arsenic-IL-2 results run counter to what has been observed in vitro, requiring further investigation.
In the Saha et al. [24] study of children living in high versus low arsenic exposure areas of Bangladesh, total white blood cells (WBC) and lymphocytes, monocytes, and eosinophils were significantly reduced among children with the highest arsenic exposure. Results from studies nested within the MINIMat study of arsenic-exposed pregnant women in Matlab, Bangladesh, revealed that arsenic exposure, as measured in maternal blood and urine, was associated with a decrease in thymic size and function in the neonate as well as an increase in infant morbidity [30, 52] and upregulation of cord blood pro-apoptotic and oxidative stress genes [52] . A cohort study by Nadeau et al. [53] of pregnant women from a region of variable exposure in New Hampshire found that increased maternal urinary arsenic concentration (μg/L) was associated with an increase in placental IL-1β expression (a proinflammatory cytokine), an increase in cord blood T cell proliferation, and alterations in cord blood T cell subsets.
Specifically, the authors noted a decrease in CD45RA + CD69
+ (naïve activated) T cells, while CD45RA + CD69 − CD294 + (naïve resting T H 2 cells) increased in cord blood. Additionally, they observed that cord blood-derived T cells exhibited greater proliferative ability in response to in vitro T cell receptor stimulation. Another study by Kile et al. [54] among pregnant Bangladeshi women found that cord blood leukocyte DNA methylation levels as well as CD4 + /CD8 + ratio were altered. In particular, for each log 10 increase in drinking water arsenic exposure, the proportion of CD8 + cells increased by 7.4%, while the proportion of CD4 + cells decreased by 9.2% [54] . The authors also noted that for each log 10 increase in arsenic exposure, B cell proportion decreased by 1.4%, following a non-significant trend (p value = 0.056). Among the genomic loci found to have increased arsenicassociated methylation were genes related to immune function, such as the tumor necrosis factor (TNF) receptor superfamily member 10b and CD151, a protein that complexes with integrin to aid in cell trafficking and motility [55] . A proteomic study of the cord blood of arsenic-exposed Mexican infants by Bailey et al. observed that the proteome was significantly altered in a manner dependent upon maternal urinary arsenic and drinking water arsenic concentrations, while pathway analysis revealed that TNF-α expression may have been at the center of this proteomic shift [56] . Finally, a case-control study in California showed that increasing ambient arsenic exposure during pregnancy and early life was associated with an increased odds ratio of the infant developing acute lymphoblastic leukemia [57] . Taken together, these studies suggest mechanisms of arsenic immunotoxicity that may hinge on immune cell subset alterations, changes in the cytokine milieu, as well as reductions in cell trafficking capacity (Fig. 1) .
Animal Studies of Arsenic Exposure and Cell-Mediated Immune Response
In Vivo Studies
In addition to the in vitro and epidemiologic literature, several animal studies have investigated cell-mediated mechanisms of arsenic immunotoxicity (Table 2) . Xu et al. [58] exposed male C57BL/6 mice via drinking water to 0, 100, or 500 ppb of As 3+ for 30 days, then assessed arsenic speciation in the bone marrow, spleen, and thymus of each animal along with levels of DNA damage in each of these tissues. The authors observed a dose-dependent increase in MMA 3+ levels in the bone marrow and thymus, which correlated with increased levels of DNA damage, demonstrating the importance of toxicokinetics as well as toxicodynamics in studies of arsenic immunotoxicity. A 2004 study by Patterson et al. attempted a suite of immunotoxicological tests of young adult female mice to evaluate the competence of their cell-mediated immune responses after arsenic exposure. In this study, Balb/c mice were treated with 50,000 ppb arsenic via drinking water for 4 weeks, resulting in reduced delayed-type contact hypersensitivity, circulating neutrophils, and immune cell proliferation, as measured by a local lymph node assay and an in vitro lymphoproliferation assay [59] . This study also observed a reduction in the recruitment of macrophages to the peritoneal cavity, however, the baseline number of peritoneal macrophages was not assessed prior to sensitization while no effect was seen in the baseline number of macrophages present in the BALF of arsenic-exposed mice when compared with controls. Importantly, these results suggest potential dysfunction in immune cell trafficking and ability to perform antigen presentation. A 2008 study of young adult male mice showed that increasing arsenic concentration (administered via gavage) was associated with reduced splenic T H cell populations along with a reduced CD4 + /CD8
+ ratio and a resulting increase in the proportion of splenic CD11b + (monocytes) cells [14] . CD11b + is a cell surface protein expressed on monocytes and macrophages (considered by some to be a panmacrophage screening tool) but is also expressed on several other cell types. Additionally, the authors showed that increasing arsenic dose was related to decreases in lymphocyte proliferation, an effect that they posited may have been related to increases in the phosphorylation level of specific kinases involved in the T cell receptor activation pathway.
Host resilience against viral challenge following arsenic exposure has been assessed in at least one study by Kozul et al. [60] . This study showed that male C57BL/6J mice exposed to 100 ppb of sodium arsenite for 5 weeks (and throughout infection) suffered worse influenza morbidity than mice not exposed to arsenic, as assessed by pulmonary viral load along with albumin, total cell infiltrate, macrophage, and neutrophil cell counts in the bronchioalveolar lavage fluid (BALF) at day 7 postinoculation. Interestingly, compared to influenza-infected mice, those mice also exposed to arsenic had higher numbers of CD8 + T cells in their BALF. Additionally, the authors observed that dendritic cells and B cells from arsenic-exposed mice were less able to traffic to the mediastinal lymph nodes (the draining lymph nodes of the lungs) at 3 days postinoculation, while primary bone marrow dendritic cells were found to be less capable of migration via a transwell assay. These assays demonstrate that arsenic may reduce the ability of antigen-presenting and antibodyforming immune cells (necessary for ramping up the adaptive immune response) to traffic to nearby lymph nodes in order to orchestrate an organized immune response to the influenza infection (Fig. 1) .
Only one study, to our knowledge, addressed questions of host immune competence in neonatal mice after prenatal and early life exposure to arsenic. In their 2013 paper, Ramsey et al. challenged 1-week-old C57BL/6 mice with influenza A virus [29••] . The investigators observed that mice exposed prenatally and perinatally to arsenic carried higher influenza A viral load in their lungs at day 7 postinoculation and higher macrophages as well as total cells in their BALF at day 3 postinoculation compared to arsenic unexposed, influenzachallenged controls. Interestingly, there was no significant difference in total lymphocytes in the BALF, despite the higher influenza A viral load in the arsenic-exposed, influenza A virus-challenged mice, suggesting that while lymphocytes may be trafficking to the site of infection, their cytotoxic capacity may have somehow been impaired by the elevated arsenic exposure.
In Vitro Studies
A few murine in vitro studies have also been conducted to investigate the effects of arsenic exposure on cell-mediated immunity ( Table 2 ). In one study by Goytia-Acevedo et al. [61] , T lymphocytes were isolated from young adult female mice and co-cultured with various doses of arsenic and mitogens PHA or Con A. The authors found that at the highest doses of sodium arsenite, T lymphocytes underwent less mitogen-stimulated proliferation when pretreated (in the case of mitogens PHA and Con A) or simultaneously cultured (in the case of mitogen PHA only) with sodium arsenite, similar to results noted by Soto-Peña et al. [14] and Kozul et al. [60] . Another study by Cho et al. [62] found that C57BL/6 splenocytes from young adult female mice exhibited reduced proliferation and IFN-γ production, as well as a nonsignificant decreasing trend in IL-2 production, when cultured with Con A, and increasing concentrations of sodium arsenite. The same downward trend in IL-2 production with increasing arsenic concentration was also noted for splenocytes cultured with anti-CD3 antibody, and the decrease was found to be significant at the highest dose of arsenic (2 μM). A similar in vitro study by Conde et al. [44] found that IL-2 expression (as measured by mRNA concentration) and secretion were reduced in a dose-dependent manner in mononuclear splenic cells cultured with increasing doses of arsenic. The highest concentration of arsenic exposure was found to inhibit ERK1/2 phosphorylation, while both concentrations of arsenic studied reduced the total number of splenic CD8 Two recent studies undertook a more in-depth investigation of the molecular mechanisms of arsenic immunotoxicity in T and B cells. Xu et al. [63•] found that suppressed Jak1, Jak3, and STAT5 signaling may be at the root of arsenic toxicity in double-negative thymocytes and potentially B cells, which rely on the same signaling pathways to develop. In a related study, Ezeh et al. [64] 
Future Directions
While the immunotoxic effects of arsenic are widely known, the specific mechanisms of these immune function alterations and how they manifest in exposed populations during critical periods of vulnerability-pregnancy, in utero, newborn, and early childhood-remain poorly understood. Considering the potential for significant arsenic-attributable infectious disease burden during these critical periods of growth and development among pregnant women and their children, this is an area that is ripe for future research and discovery. One important area for future research relates to the impact of arsenic exposure on barrier tissue maintenance, such as in the lungs. While this is not direct immunotoxicity, loss of barrier integrity can be a strong driver of susceptibility to numerous infectious diseases, particularly respiratory infections. A recent study by Ramsey et al. [65] showed that prenatal exposure of C57BL/6 mice to arsenic resulted in neonatal lungs that were smaller, less elastic, and that exhibited differential expression of many genes involved in mucociliary function. The pulmonary effects of arsenic exposure have important human health implications. In a 2013 retrospective cohort study by Smith et al., the authors found that Bangladeshi children in the highest in utero arsenic exposure category had a significantly elevated OR of asthma, wheezing while not having a cold, and shortness of breath when walking fast or on flat ground. A 2007 study by Islam et al. assessed the relationship between arsenic exposure, respiratory symptoms, and serum Ig profiles in arsenicosis patients compared to unexposed controls [20] . The authors found that high arsenic exposure was associated with a high prevalence of respiratory conditions such as asthma, bronchitis, cough, and chest sounds. Others have documented arsenic-related exacerbation of non-malignant lung disease and bronchiectasis severity [67] . All of these studies point to mechanisms of pulmonary toxicity by arsenic, with the potential to lead to immune-mediated disease and infection susceptibility later in life.
Another area for future research would be determining the most critical exposure windows during the prenatal, perinatal, and postnatal periods. Throughout the life of the mother and father as well as during gestation and early life development of the child, there exist critical windows of organ system development as well as changes in DNA methylation status [7, [68] [69] [70] [71] . The immune effects that arsenic exposure can elicit in the host, similar to effects associated with other toxic chemicals [72] [73] [74] [75] , may differ dramatically depending on the developmental period during which exposure occurs. However, little is known about this topic.
Another area for future research is the potential role of arsenic exposure in altering maternal immune response to vaccination and maternal antibody production and transplacental transfer efficiency. Although arsenic [18•, 24] and other environmental toxicants [72] [73] [74] [75] appear to impair immune responses to vaccinations in childhood, little is known about whether arsenic can impair maternal antibody responses to vaccination and the transfer of maternal antibody to the newborn [76] . There are several critical prenatal, perinatal, and postnatal and early childhood development periods that would benefit from focused future longitudinal studies. Assessment of maternal and child immune responses to one or more vaccinations that have known health benefits and are recommended for pregnant women and their newborns, such as influenza (recommended at any point during pregnancy [77] ) and hepatitis B (recommended at birth by CDC [78] ), could improve understanding of arsenic-related mechanisms and pathways of immunotoxicity. Knowledge of specific mechanisms could lead to prioritization of interventions (changes in vaccine dosage; administration of booster doses) in areas where persistent arsenic exposure cannot readily be remediated due to the complexity of exposure sources (e.g., food, water, occupation) and resource limitations. Additionally, by prospectively collecting samples such as peripheral blood serum, drinking water, and urine, researchers will help to build important knowledge of the temporal effects of exposure, including when and how external exposure and arsenic metabolism affect maternal, fetal, and neonatal immunity and how early life exposure may influence infectious disease outcomes into childhood and adulthood. While some studies have demonstrated that arsenic exposure increases total antibody titers in the serum [20, 31••, 79] , the effects of arsenic on the production of antigen-specific antibodies seem to differ depending on the antigen [24, 41] . It would be useful to know if this is a result of loss of antigenspecific T H cells, a loss of the ability of these T H cells to home to local lymph nodes, or an inability of these T H cells to properly activate B cells to differentiate into plasma and memory B cells and to initiate affinity maturation (Fig. 1 ). The precise mechanism or suite of mechanisms involved in this progression remains a fundamental knowledge gap, one that could be closed by future in vivo and epidemiologic studies.
Moreover, factors that affect arsenic metabolism and toxicity outcomes, specifically micronutrients critical for onecarbon metabolism (e.g., folate and vitamins B2, B6, and B12), [80] [81] [82] , have not been evaluated in studies of arsenic immunotoxicity, correlates of vaccine-induced protection, placental transfer of maternal antibodies, or morbidity in mothers and newborns. In order to fill these knowledge gaps, future studies should measure micronutrient intake as well as external sources of arsenic exposure (e.g., drinking water, food) as well as arsenic metabolism (e.g., inorganic arsenic, dimethylarsinic acid (DMA), and monomethylarsonic acid (MMA) in urine).
Respiratory infections during the prenatal, perinatal, and postnatal period are of great concern for maternal and child health. Animal studies have shown arsenicrelated exacerbation of severe influenza infection following in utero and early life arsenic exposure [29••, 60, 83] . Similarly, human studies also indicate arsenicrelated exacerbation of self-reported respiratory morbidity symptoms during pregnancy and early life [20, 25, 26, 28, 30, 66] , but no human arsenic exposure studies to our knowledge have employed objective measures of respiratory morbidity (e.g., laboratory-confirmed infection via tests of seroconversion and/or pathogen isolation) during pregnancy and early life.
Continuance of these gaps limits understanding of critical immunologic mechanisms, processes, and pathways. This represents an important problem because until filled, optimal points for intervention to prevent arsenic-related immunotoxicity and morbidity during pregnancy and early life will not be known. Future in vitro and epidemiological studies should focus on building upon knowledge of arsenic immunotoxicity mechanisms by integrating enumerative and functional measures of antibody and immune cell (CD4 + , CD8 + T cells) responses in regions with varying arsenic exposure to determine how arsenic alters humoral and cellmediated immunity and susceptibility to infection among pregnant women and their neonates and children during early life.
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